Stephanie R Harrison1, Dennis McGonagle1, Sharmin Nizam2, Stephen Jarrett2, Jeroen van der Hilst3,4, Michael F McDermott1, Sinisa Savic1,5. 1. NIH Research-Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU) and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St. James's University Hospital, Beckett Street, Leeds, United Kingdom. 2. Department of Rheumatology, Pinderfields Hospital, Wakefield, United Kingdom. 3. Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium. 4. BIOMED Research Institute, University of Hasselt, Hasselt, Belgium. 5. Department of Clinical Immunology and Allergy, St. James's University Hospital, Leeds, United Kingdom.
Abstract
BACKGROUND: Some adult patients presenting with unexplained pyrexia, serositis, skin rashes, arthralgia, myalgia, and other symptoms commonly found in autoinflammatory disorders may not fit a specific diagnosis, either because their clinical phenotype is nondiagnostic or genetic tests are negative. We used the term undifferentiated systemic autoinflammatory disorder (uSAID) to describe such cases. Given that well-defined autoinflammatory diseases show responses to IL-1 blockade, we evaluated whether anakinra was useful for both diagnosing and treating uSAID patients. METHODS: We performed a retrospective analysis of consecutive patients presenting with uSAID between 2012-2015 who were treated with the recombinant IL-1 receptor antagonist anakinra. uSAID was diagnosed after excluding malignancy, infection, and pathogenic mutations in known hereditary fever syndromes (HFS) genes and where clinical criteria for adult onset Still's disease (AOSD) were not met. RESULTS: A total of 11 patients presented with uSAID (5 males and 6 females), with a mean time to diagnosis of 3.5 years (1-8 years). Patients were unresponsive or only partially controlled on disease-modifying antirheumatic drug (DMARD)/steroid treatment. Anakinra controlled symptoms within 4-6 weeks of starting treatment in 9 of 11 cases. Two patients discontinued therapy - one due to incomplete response and another due to severe injection-site reactions. CONCLUSION: This retrospective case series demonstrates that the spectrum of poorly defined autoinflammatory disorders that show responsiveness to anakinra is considerable. Anakinra seems a viable treatment option for these patients, who are unresponsive to standard steroid/DMARD treatments. Moreover, given the mechanisms of action, response to anakinra implicates underlying IL-1 dysregulation in the disease pathogenesis of responding uSAIDs patients.
BACKGROUND: Some adult patients presenting with unexplained pyrexia, serositis, skin rashes, arthralgia, myalgia, and other symptoms commonly found in autoinflammatory disorders may not fit a specific diagnosis, either because their clinical phenotype is nondiagnostic or genetic tests are negative. We used the term undifferentiated systemic autoinflammatory disorder (uSAID) to describe such cases. Given that well-defined autoinflammatory diseases show responses to IL-1 blockade, we evaluated whether anakinra was useful for both diagnosing and treating uSAID patients. METHODS: We performed a retrospective analysis of consecutive patients presenting with uSAID between 2012-2015 who were treated with the recombinant IL-1 receptor antagonist anakinra. uSAID was diagnosed after excluding malignancy, infection, and pathogenic mutations in known hereditary fever syndromes (HFS) genes and where clinical criteria for adult onset Still's disease (AOSD) were not met. RESULTS: A total of 11 patients presented with uSAID (5 males and 6 females), with a mean time to diagnosis of 3.5 years (1-8 years). Patients were unresponsive or only partially controlled on disease-modifying antirheumatic drug (DMARD)/steroid treatment. Anakinra controlled symptoms within 4-6 weeks of starting treatment in 9 of 11 cases. Two patients discontinued therapy - one due to incomplete response and another due to severe injection-site reactions. CONCLUSION: This retrospective case series demonstrates that the spectrum of poorly defined autoinflammatory disorders that show responsiveness to anakinra is considerable. Anakinra seems a viable treatment option for these patients, who are unresponsive to standard steroid/DMARD treatments. Moreover, given the mechanisms of action, response to anakinra implicates underlying IL-1 dysregulation in the disease pathogenesis of responding uSAIDs patients.
Authors: M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota Journal: J Rheumatol Date: 1992-03 Impact factor: 4.666
Authors: Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis Journal: Arthritis Rheum Date: 2008-08
Authors: Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins Journal: N Engl J Med Date: 2009-06-04 Impact factor: 91.245
Authors: Hal M Hoffman; Sanna Rosengren; David L Boyle; Jae Y Cho; Jyothi Nayar; James L Mueller; Justin P Anderson; Alan A Wanderer; Gary S Firestein Journal: Lancet Date: 2004 Nov 13-19 Impact factor: 79.321
Authors: Francesca Della Casa; Antonio Vitale; Giuseppe Lopalco; Piero Ruscitti; Francesco Ciccia; Giacomo Emmi; Marco Cattalini; Ewa Wiesik-Szewczyk; Maria Cristina Maggio; Benson Ogunjimi; Petros P Sfikakis; Abdurrahman Tufan; Sulaiman M Al-Mayouf; Emanuela Del Giudice; Emma Aragona; Francesco La Torre; Jurgen Sota; Sergio Colella; Ilenia Di Cola; Daniela Iacono; Irene Mattioli; Karina Jahnz-Rózyk; Rik Joos; Katerina Laskari; Carla Gaggiano; Anna Abbruzzese; Paola Cipriani; Gelsomina Rozza; Alhanouf AlSaleem; Derya Yildirim; Maria Tarsia; Gaafar Ragab; Francesca Ricci; Fabio Cardinale; Marcelina Korzeniowska; Micol Frassi; Valeria Caggiano; Moustafa Ali Saad; Rosa Maria Pereira; Virginia Berlengiero; Stefano Gentileschi; Silvana Guerriero; Teresa Giani; Viviana Gelardi; Florenzo Iannone; Henrique Ayres Mayrink Giardini; Ibrahim A Almaghlouth; Riza Can Kardas; Djouher Ait-Idir; Bruno Frediani; Alberto Balistreri; Claudia Fabiani; Donato Rigante; Luca Cantarini Journal: Front Med (Lausanne) Date: 2022-06-10